tradingkey.logo

Procept Biorobotics Corp

PRCT
查看詳細走勢圖
28.740USD
+1.340+4.89%
收盤 02/06, 16:00美東報價延遲15分鐘
1.61B總市值
虧損本益比TTM

Procept Biorobotics Corp

28.740
+1.340+4.89%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.89%

5天

-0.76%

1月

-17.20%

6月

-37.10%

今年開始到現在

-8.65%

1年

-59.40%

查看詳細走勢圖

TradingKey Procept Biorobotics Corp股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Procept Biorobotics Corp當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名34/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為52.75。中期看,股價處於平穩狀態。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Procept Biorobotics Corp評分

相關信息

行業排名
34 / 205
全市場排名
122 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看跌

Procept Biorobotics Corp亮點

亮點風險
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
業績高增長
公司營業收入穩步增長,連續3年增長199.27%
估值高估
公司最新PE估值-18.74,處於3年歷史高位
機構減倉
最新機構持股59.67M股,環比減少3.70%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉1.34K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.66

分析師目標

基於 14 分析師
買入
評級
52.750
目標均價
+92.52%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Procept Biorobotics Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Procept Biorobotics Corp簡介

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
公司代碼PRCT
公司Procept Biorobotics Corp
CEOWood (Larry L)
網址https://www.procept-biorobotics.com/
KeyAI